{"product_id":"bayer-business-model-canvas","title":"Bayer Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer Business Model Canvas - Clear Blueprint for Growth, R\u0026amp;D and Integrated Value Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Bayer's Business Model Canvas to see how scientific expertise and cross‑sector capabilities translate into sustainable value across healthcare and agriculture. This concise, structured overview highlights the company's value propositions, customer segments, revenue and partnership models, and R\u0026amp;D-driven scaling levers-providing investors, strategists and industry leaders with practical insight to assess monetization logic and strategic priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R\u0026amp;D Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs strategic R\u0026amp;D collaborations with universities and biotech firms to share drug-discovery and agri-tech risks, co-funding projects that cut upfront costs-Bayer reported ~€1.8bn in external R\u0026amp;D investments and partnerships in 2024. By late 2025 Bayer pivoted more capital toward cell and gene therapy and next-gen biologicals, citing a 35% increase in alliance deal volume year-over-year and several co-funded trials entering Phase II.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer depends on a global network of 1,200+ logistics and wholesale partners to distribute medicines and crop inputs across 90+ countries; in 2024 this network moved products generating €44.1bn in pharma and crop science revenues, ensuring delivery to pharmacies and 25m+ farm customers. Strengthening these ties is crucial to sustain market share in emerging economies and remote regions where last-mile costs can add 8-15% to distribution spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and AgTech Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with tech providers and data analytics firms power Bayer's Climate FieldView and precision farming, integrating satellite imagery, soil sensors, and AI to deliver field-level insights; by 2024 FieldView covered ~95 million hectares globally and helped users increase yields by up to 6% in pilot studies. These alliances cut inputs and emissions-partner data show up to 12% fertilizer reduction-so farmers boost productivity while lowering environmental footprints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer partners with hospitals, insurers and national health services to secure reimbursement and patient access for specialty medicines, using real-world evidence to demonstrate value; in 2024 Bayer Pharmaceuticals reported core EPS contributing to a €49.0bn Group sales run-rate, strengthening payer negotiations.\u003c\/p\u003e\n\u003cp\u003eIn 2025 these ties shift toward value-based care and integrated pathways, with pilots linking outcomes to payments-Bayer cites outcome-based contracts in oncology and rare disease pilots covering ~5-10% of eligible patient cohorts in EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reimbursement and access for specialty meds\u003c\/li\u003e\n\u003cli\u003e2024 Group sales context: €49.0bn (Bayer, FY 2024)\u003c\/li\u003e\n\u003cli\u003e2025 emphasis: value-based contracts, integrated care pathways\u003c\/li\u003e\n\u003cli\u003ePilot scale: ~5-10% eligible patients in EU outcome pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer forms joint ventures with environmental NGOs and carbon-credit platforms to hit its 2030 sustainability goals, targeting a 30% reduction in Scope 1+2 emissions and scaling regenerative agriculture across 5 million hectares by 2030, creating paid carbon services for farmers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint ventures: NGOs + marketplaces\u003c\/li\u003e\n\u003cli\u003eTargets: 30% Scope 1+2 cut by 2030\u003c\/li\u003e\n\u003cli\u003eScale: 5M hectares regenerative ag by 2030\u003c\/li\u003e\n\u003cli\u003eRevenue shift: product to paid services\/carbon credits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer scales services, data \u0026amp; sustainability-€1.8bn R\u0026amp;D, 95M ha FieldView, 2030 targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer leverages 1,200+ distribution partners, ~€1.8bn external R\u0026amp;D spend (2024), FieldView on ~95M ha, and joint ventures targeting 30% Scope 1+2 cut and 5M ha regenerative ag by 2030, shifting revenue toward services and value-based care pilots covering ~5-10% eligible EU patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution partners\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e€1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView coverage\u003c\/td\u003e\n\u003ctd\u003e95M ha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Pharma\/Crop sales\u003c\/td\u003e\n\u003ctd\u003e€44.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€49.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue‑based pilot scale (2025)\u003c\/td\u003e\n\u003ctd\u003e5-10% eligible patients EU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2030 targets\u003c\/td\u003e\n\u003ctd\u003e30% Scope1+2 cut; 5M ha regen ag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Bayer detailing nine BMC blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned with real-world operations, competitive advantages, SWOT-linked insights, and polished for presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Bayer's business model with editable cells, condensing R\u0026amp;D, product portfolios, and regulatory pathways into a one-page snapshot that saves hours of structuring and is ready for team collaboration or boardroom review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContinuous R\u0026amp;D investment funds discovery of new molecular entities in pharmaceuticals and novel crop traits, drives complex clinical trials and regulatory filings, and supports long-term lab work; Bayer spent €5.3bn on R\u0026amp;D in 2024 and reported ~35 active Phase I-III programs. By end-2025 AI-driven drug discovery reduced early lead times by roughly 30%, accelerating candidate ID and lowering preclinical costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs 120+ high-tech production sites worldwide to make chemical compounds, biologicals, and consumer health products, enforcing Good Manufacturing Practices (GMP) and strict environmental rules; in 2024 manufacturing accounted for ~48% of Bayer's €44.1bn revenue, supporting supply consistency and quality across Crop Science, Pharmaceuticals, and Consumer Health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer deploys a specialized sales force of ~25,000 reps (2024 figure) to train healthcare professionals and give technical support to large-scale agricultural producers, driving €4.3bn in Crop Science services-related revenue in 2024. Marketing is locally adapted to regulations and cultures across 90+ markets, and by 2025 digital marketing plus e-commerce account for ~28% of Consumer Health sales, up from 18% in 2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Patent Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and patent management keep Bayer's IP and market access intact: Bayer filed ~2,200 patents worldwide in 2024 and spent €3.1bn on regulatory and safety affairs in 2023 to meet FDA and EFSA standards, protecting product lifecycles and revenue streams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,200 patents filed (2024)\u003c\/li\u003e\n\u003cli\u003e€3.1bn regulatory spend (2023)\u003c\/li\u003e\n\u003cli\u003eMaintains FDA\/EFSA approvals for global markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transformation and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIntegrating digital tools across Bayer-from precision breeding to patient monitoring-drives efficiencies and new products; by late 2025 Bayer reports using data analytics to cut supply‑chain lead times by ~12% and to improve demand-forecast accuracy by ~15% (internal pilots across Crop Science and Pharmaceuticals).\u003c\/p\u003e\n\u003cp\u003eManaging petabytes of agronomic, clinical, and IoT data funds platform products and services that aim to add €500m+ ARR by 2026 while lowering unit costs through predictive maintenance and SKU-level forecasting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData-driven supply chain: ~12% lead-time cut\u003c\/li\u003e\n\u003cli\u003eForecast accuracy: ~15% improvement\u003c\/li\u003e\n\u003cli\u003eTarget digital ARR: €500m+ by 2026\u003c\/li\u003e\n\u003cli\u003eScope: petabytes from field sensors, trials, patient devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer ramps R\u0026amp;D €5.3B, 35 drug programs, 120+ sites and €500M+ digital ARR target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer invests €5.3bn in R\u0026amp;D (2024) with ~35 active Phase I-III programs, runs 120+ GMP sites, employs ~25,000 sales reps, filed ~2,200 patents (2024), spent €3.1bn on regulatory (2023), and aims €500m+ digital ARR by 2026 while cutting supply lead times ~12% and forecast error ~15% by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e€5.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical programs\u003c\/td\u003e\n\u003ctd\u003e~35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps (2024)\u003c\/td\u003e\n\u003ctd\u003e~25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents filed (2024)\u003c\/td\u003e\n\u003ctd\u003e~2,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend (2023)\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital ARR target (2026)\u003c\/td\u003e\n\u003ctd\u003e€500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply lead-time cut\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecast accuracy gain\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Bayer Business Model Canvas shown here is the actual deliverable, not a sample or mockup; it's a direct snapshot of the exact file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you'll get this same professional, fully editable document-structured and formatted exactly as previewed, ready for presentation or customization.\u003c\/p\u003e\n\u003cp\u003eNo placeholders, no surprises-what you see is the file you'll own and download instantly in its complete form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer's intellectual property portfolio-over 40,000 worldwide patents and pending filings as of 2025-covers drug formulations, seed traits, and chemical-manufacturing processes, creating a durable competitive moat and enabling temporary market exclusivity that supports pricing power; patents underpin valuation (market cap ~79 billion EUR on 31 Dec 2025) and long-term revenue streams, notably in pharmaceuticals and crop science.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Capital and Scientific Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer employs ~100,000 people worldwide, including roughly 20,000 scientists, researchers, and agronomists, whose expertise underpins R\u0026amp;D spend of €6.6 billion in 2024; attracting biotech and data-science talent is key to its pipeline, enabling complex solutions across pharmaceuticals and crop science that target global health and food security challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Production Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eModern manufacturing plants and specialized laboratories are core physical capital for Bayer, enabling high-precision chemical synthesis and biologics production that are hard to replicate; as of 2025 Bayer reports over 70 global production sites with roughly €3.4bn in capital expenditure since 2020 on automation and sustainability upgrades, lifting capacity and reducing energy use per unit by ~18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer's global distribution network-more than 100 country operations, ~300 warehouses, and integrated digital platforms-combines physical logistics (including cold-chain for specialty medicines) with farmer-facing apps to deliver products efficiently and expand market share in established and high-growth markets.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Bayer reported ~€52 billion net sales, with emerging markets contributing ~30%, underscoring how the distribution footprint converts supply capability into revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e100+ countries covered\u003c\/li\u003e\n\u003cli\u003e~300 warehouses globally\u003c\/li\u003e\n\u003cli\u003eCold-chain for specialty medicines\u003c\/li\u003e\n\u003cli\u003eFarmer digital platforms for engagement\u003c\/li\u003e\n\u003cli\u003eEmerging markets ≈30% of 2024 sales (€52bn)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProprietary datasets from Climate FieldView and Bayer's clinical databases power precision agriculture and personalized medicine, driving targeted product recommendations and trials; FieldView had over 410,000 active users and covered ~74 million hectares globally by end-2024, rising monetization via subscriptions and analytics fees through 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Bayer expects digital revenue growth from services to exceed low-double-digit percent CAGR versus 2022, turning data into recurring service margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e410,000+ FieldView users (2024)\u003c\/li\u003e\n\u003cli\u003e~74 million hectares covered (2024)\u003c\/li\u003e\n\u003cli\u003eData-enabled services shifting to subscription\/analytics models\u003c\/li\u003e\n\u003cli\u003eDigital services projected low-double-digit CAGR through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer: 40,000+ patents, €6.6bn R\u0026amp;D, 100k staff, €52bn sales-global scale \u0026amp; digital reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's key resources: 40,000+ patents (2025), ~100,000 employees incl. ~20,000 R\u0026amp;D staff, €6.6bn R\u0026amp;D (2024), 70+ production sites, €3.4bn capex since 2020, 100+ country ops, ~300 warehouses, FieldView 410,000 users\/74m ha (2024), €52bn sales (2024), emerging markets ~30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003e40,000+ patents (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople\u003c\/td\u003e\n\u003ctd\u003e~100,000 total; ~20,000 R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€6.6bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapEx\u003c\/td\u003e\n\u003ctd\u003e€3.4bn since 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\u003c\/td\u003e\n\u003ctd\u003e70+ production sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e100+ countries; ~300 warehouses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eFieldView 410,000 users; 74m ha (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e€52bn (2024); EM ~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Pharmaceutical Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer delivers life-saving cardiovascular, oncology, and women's health therapies that target unmet needs and boost outcomes; specialty medicines drove Bayer's Pharmaceuticals 2024 sales of €17.8bn and focus in 2025 on high‑value, personalized treatments aims to raise margins and patient response rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Yield and Resilient Crop Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Crop Science division supplies seeds, traits, and crop protection that raise yields by up to 20% per hectare and cut input use (water, fertilizer, pesticides) by ~15% per Bayer field trial, vital as arable land falls 10% per capita since 2000 and climate shocks doubled crop losses; integrated digital tools (Climate FieldView) boost ROI, lowering input costs by ~12% and improving nitrogen use efficiency by 8% in 2024 pilot data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrusted Consumer Health Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer's trusted consumer health portfolio-including Bayer Aspirin and Bepanthen-delivers accessible OTC solutions for pain, nutrition, and dermatology, supporting daily self-care for over 100 million consumers annually; in 2024 the consumer health segment reported ~3.2 billion euros in sales, underscoring trust and scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and Precision Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital Farming and Precision Insights shift Bayer from product sales to data-driven solutions by offering platforms (Climate FieldView, xarvio) that cut input use by ~12% and raise yields ~5% on average, improving farm EBITDA and lowering weather\/price risk.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, Bayer cites \u0026gt;10 million hectares under digital management, making insights a market differentiator and supporting higher-margin services and recurring revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput reduction ~12%\u003c\/li\u003e\n\u003cli\u003eYield lift ~5%\u003c\/li\u003e\n\u003cli\u003e\u0026gt;10M hectares managed (2025)\u003c\/li\u003e\n\u003cli\u003eMore recurring, higher-margin services\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Sustainability and ESG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer ties business targets to global sustainability goals-committing to halve greenhouse gas emissions by 2030 and reach carbon neutrality in its own operations by 2035-reducing agricultural environmental impact and appealing to ESG-focused investors and regulators.\u003c\/p\u003e\n\u003cp\u003eThe Science for a better life slogan strengthens consumer trust: 2024 sustainability-linked revenues (products\/services marketed with ESG claims) grew ~8% year-over-year, attracting capital and premium pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2030: 50% GHG cut target\u003c\/li\u003e\n\u003cli\u003e2035: carbon neutral operations\u003c\/li\u003e\n\u003cli\u003e2024: ESG-linked revenue +8% YoY\u003c\/li\u003e\n\u003cli\u003eStronger regulator\/investor appeal, higher pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer: €21B+ health \u0026amp; pharma, digital farming \u0026gt;10M ha-cut inputs 12%, lift yields 5%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer offers high‑value specialty medicines (Pharma sales €17.8bn in 2024) and scalable Crop Science inputs plus digital farming (\u0026gt;10M ha managed by 2025) that cut inputs ~12% and lift yields ~5%, backed by a trusted consumer health portfolio (€3.2bn 2024) and ESG targets (50% GHG cut by 2030, carbon‑neutral ops by 2035).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales\u003c\/td\u003e\n\u003ctd\u003e€17.8bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e€3.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital hectares\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput reduction\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYield lift\u003c\/td\u003e\n\u003ctd\u003e~5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGHG target\u003c\/td\u003e\n\u003ctd\u003e50% by 2030; neutral ops 2035\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Consultative Selling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Crop Science and Pharmaceuticals Bayer uses technical advisors and medical science liaisons to deliver tailored support, driving adoption of complex products; in 2024 Bayer reported ~22% of R\u0026amp;D-related field staff deployed to customer engagement, helping sustain a \u0026gt;70% repeat-purchase rate in key markets. This high-touch model improves safety, ensures effective use, and builds long-term loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Loyalty and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn Bayer Consumer Health, brand loyalty stems from consistent product quality and mass-market marketing; 2024 sales of 4.8 billion euros in Consumer Health show consumers trusting legacy brands for self-care, and Bayer reports a net promoter score (NPS) near industry average, supported by transparency in labeling and GMP (good manufacturing practice) standards across its portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Self-Service\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDigital platforms like Climate FieldView enable continuous, data-driven engagement with farmers, delivering personalized recommendations and real-time feedback that shift relationships from one-off sales to ongoing partnerships; Bayer reported over 6 million active FieldView users globally by 2025, with digital subscription revenue growing ~22% year-over-year in 2024. In 2025, mobile apps and online portals serve as primary touchpoints for core segments, accounting for roughly 60% of customer interactions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKey Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer uses dedicated key-account teams for hospital networks, governments, and large agricultural clients, managing relationships via long-term contracts and collaborative R\u0026amp;D to co-develop scalable solutions; in 2024 Bayer reported ~24% of Pharma sales and ~30% of Crop Science sales tied to institutional or channel partnerships.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated teams for hospitals, govts, industrial farms\u003c\/li\u003e\n\u003cli\u003eLong-term contracts + collaborative agreements\u003c\/li\u003e\n\u003cli\u003eCo-development of tailored, large-scale solutions\u003c\/li\u003e\n\u003cli\u003e~24% Pharma, ~30% Crop Science sales from institutional partnerships (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer partners with patient groups across oncology, cardiology, and rare diseases to shape care pathways; in 2024 Bayer funded patient programs reaching over 1.2 million people and reported a 14% lift in therapy adherence in pilot support cohorts.\u003c\/p\u003e\n\u003cp\u003eEducational resources, digital coaching, and reimbursement support reduce hospital visits and improve chronic-condition management, reinforcing Bayer's patient-centric reputation and aiding market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: 1.2M patients reached\u003c\/li\u003e\n\u003cli\u003e14% increase in adherence (pilot)\u003c\/li\u003e\n\u003cli\u003eFocus: oncology, cardiology, rare diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer blends high-touch field teams and digital scale to boost repeat sales \u0026amp; subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer pairs high-touch field teams (22% of R\u0026amp;D field staff in 2024) and key-account management with mass-market Consumer Health channels, digital platforms (6M+ Climate FieldView users by 2025) and patient programs (1.2M reached in 2024) to drive \u0026gt;70% repeat purchases, institutional sales ~24% Pharma\/~30% Crop Science (2024), and digital subscription growth ~22% YoY (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D field staff on customer engagement (2024)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat-purchase rate (key markets)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView users (2025)\u003c\/td\u003e\n\u003ctd\u003e6M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital subscription growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~22% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€4.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients reached (2024)\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales share (2024)\u003c\/td\u003e\n\u003ctd\u003ePharma ~24% \/ Crop Science ~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly trained internal sales force engages directly with physicians, pharmacists, and large agricultural producers, explaining complex, high-value Bayer products and securing bulk contracts; Bayer reported ~30,000 field-based sales reps globally in 2024, driving ~40% of pharma and crop science B2B revenues. This channel remains the most effective B2B relationship manager in life sciences, converting higher-value deals with average order sizes 3-5x greater than indirect channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Bayer's physical products reach end-users via third-party wholesalers, pharmacies, and agri-retailers, with over 70% of pharmaceutical volume and 85% of crop-protection sales routed through partners in 2024-2025; this network keeps availability in remote areas and supports 2025 revenue resilience as Bayer reported €46.0bn sales in 2024. Managing channel partners in 2025 is critical to defend share vs local competitors and to sustain distribution margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Online Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Consumer Health division has scaled digital storefronts and online-pharmacy listings, driving a 23% rise in e-commerce sales in 2024 and reaching customers in 120+ countries with lower channel costs than brick-and-mortar. Online pharmacies and marketplaces capture convenience-driven demand-38% of global OTC purchases moved online in 2024-improving margins and enabling targeted promotions with real-time sales data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platforms and Apps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpproprietary digital tools like climate fieldview act as both product and channel delivering agronomic insights services directly to farmers devices enabling two-way data exchange had over active users globally by end-2024 contributed bayer revenue growth crop science sales up in\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFieldView: 500,000+ users (2024)\u003c\/li\u003e\n\u003cli\u003eDirect data flow: device-to-cloud-to-advisors\u003c\/li\u003e\n\u003cli\u003eDrives services revenue; boosts retention\u003c\/li\u003e\n\n\u003c\/pproprietary\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical and Scientific Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer leverages medical and scientific symposia and peer-reviewed journals to publish clinical data, reinforcing credibility for new drugs; in 2024 Bayer reported €48.3bn revenue with Pharma contributing €15.4bn, and company-funded publications and conference presentations drove key opinion leader adoption and formulary consideration.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConferences and journals shape expert opinion\u003c\/li\u003e\n\u003cli\u003eIndirect sales via KOLs and guideline citations\u003c\/li\u003e\n\u003cli\u003e2024 Pharma revenue €15.4bn-clinical credibility boosts uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel growth fuels €46bn sales-30k reps, 500k FieldView users, +23% e‑commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInternal sales reps (~30,000 in 2024) drive ~40% of B2B life-science revenue; wholesalers\/pharmacies handle 70-85% of volume; Consumer Health e‑commerce +23% in 2024; FieldView 500,000+ users; 2024 sales €46.0bn (total) \/ Pharma €15.4bn; channels sustain margins and market access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField reps\u003c\/td\u003e\n\u003ctd\u003e~30,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView users\u003c\/td\u003e\n\u003ctd\u003e500,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ee‑commerce growth (Consumer Health)\u003c\/td\u003e\n\u003ctd\u003e+23%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesaler\/pharmacy volume\u003c\/td\u003e\n\u003ctd\u003e70-85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003e€46.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma sales\u003c\/td\u003e\n\u003ctd\u003e€15.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHealthcare professionals and providers-doctors, specialists, and hospital administrators-prescribe or buy Bayer pharmaceuticals based on clinical efficacy, safety, and cost-effectiveness; in 2024 Bayer reported €17.6 billion in Pharmaceuticals revenue, underscoring product impact on hospital formularies. Bayer supplies evidence packages, real-world data and decision-support tools-over 120 peer-reviewed trials in 2023-so clinicians can improve patient outcomes and justify formulary choices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge-Scale Commercial Farmers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfessional farmers managing 1,000+ acres are Bayer's core buyers for high-tech seeds and digital tools, accounting for roughly 60% of global commercial seed sales in 2024 and driving over €4.3bn in Crop Science revenue in 2024. They use precision tech and advanced genetics to raise yields and cut costs-average yield gains 8-12%-and by 2025 prioritize sustainable\/regenerative practices, with 42% adopting cover crops or reduced tillage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Consumer Health segment targets everyday consumers seeking over-the-counter remedies and wellness products; these buyers prioritize Bayer's brand trust, retail reach, and simple dosing. In 2024 Bayer Consumer Health generated about €3.4bn in sales, and purchase decisions are driven by store availability and digital ads-34% of shoppers in 2023 cited online search or social media as the trigger for OTC purchases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpnational health services and agricultural ministries buy bayer products for public programs food security in governments accounted about of sales driven by large vaccine crop-protection seed contracts focused on population supply stability.\u003e\n\u003cpnegotiations center on value-based pricing and measurable social impact so bayer ties to outcomes like reduced malnutrition rates or yield improvements public tenders often span years require epidemiological agronomic data.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovt share ~18% of 2024 sales (€9.1bn)\u003c\/li\u003e\n\u003cli\u003eContracts often 5-10 years\u003c\/li\u003e\n\u003cli\u003eFocus: population health, food-supply stability\u003c\/li\u003e\n\u003cli\u003ePricing: value-based, outcome-linked\u003c\/li\u003e\n\u003cli\u003eRequires epidemiologic\/agronomic impact data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnegotiations\u003e\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmallholder Farmers in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer targets smallholder farmers in Africa and Asia-about 500 million smallholders globally-offering affordable seed, crop protection, and digital advisory; Crop Science sees this as a long-term growth pool as emerging markets accounted for ~28% of 2024 sales (€7.6bn of €27.1bn).\u003c\/p\u003e\n\u003cp\u003eThese farmers need scalable inputs, micro‑financing, and on‑field training to boost yields; Bayer invests in training programs and partnerships to raise adoption and lifetime customer value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~500 million smallholders worldwide\u003c\/li\u003e\n\u003cli\u003eEmerging markets ~28% of Crop Science 2024 sales (€7.6bn)\u003c\/li\u003e\n\u003cli\u003eNeeds: low‑cost inputs, microcredit, technical training\u003c\/li\u003e\n\u003cli\u003eStrategic: long‑term growth, food security alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer 2024: €50.7bn driven by Pharma, Crop Science, gov't contracts \u0026amp; 500M smallholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHealthcare providers, professional farmers (1,000+ acres), consumers, governments, and ~500M smallholders drive Bayer's 2024 €50.7bn sales: Pharmaceuticals €17.6bn, Crop Science €27.1bn (emerging markets €7.6bn), Consumer Health €3.4bn; governments ~18% (€9.1bn); core asks: clinical\/economic evidence, precision ag, brand trust, value‑based contracts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 €bn\u003c\/th\u003e\n\u003cth\u003eKey metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmaceuticals\u003c\/td\u003e\n\u003ctd\u003e17.6\u003c\/td\u003e\n\u003ctd\u003e120+ trials (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop Science\u003c\/td\u003e\n\u003ctd\u003e27.1\u003c\/td\u003e\n\u003ctd\u003eEmerging €7.6bn; 60% seed sales pro farmers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e3.4\u003c\/td\u003e\n\u003ctd\u003e34% online-triggered buys (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\u003c\/td\u003e\n\u003ctd\u003e9.1\u003c\/td\u003e\n\u003ctd\u003e18% sales; 5-10y tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmallholders\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e~500M; long-term growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is one of Bayer's largest cost centers: developing a single new pharmaceutical or seed trait can cost $1-2.6 billion and often fails before commercialization, making these expenses high-risk.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Bayer still allocates roughly 11-13% of revenue to R\u0026amp;D-about €5.5-6.5 billion annually-to sustain its innovation pipeline and late-stage clinical and agri-biotech programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of running Bayer's global production network-covering 149 manufacturing sites in 2024-drives major expenses: raw materials, labor, and energy for chemical synthesis plus advanced CAPEX for biologics; R\u0026amp;D and quality control add material ongoing costs. Energy price swings and 2021-24 supply-chain shocks raised input and logistics costs by about 8-12% year-over-year for the industry, pushing Bayer's COGS pressure in recent filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Commissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Bayer's global sales force and large-scale marketing campaigns consumes major resources-Bayer reported SG\u0026amp;A of €10.8bn in FY2024, with marketing, digital ads, events, and technical support driving a sizable share to defend market share in pharma and crop science; digital ad spend and professional events alone often represent 5-8% of product-line revenues, necessary to sustain volume in highly competitive markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegal, Regulatory, and Litigation Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBayer spends heavily on patent filings, regulatory compliance, and litigation-Crop Science drove €10.9bn legal\/settlement provisions in 2020-2023 litigation-related outflows and ongoing reserve needs; managing these unpredictable costs is central to liquidity planning.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge patent\/regulatory spend\u003c\/li\u003e\n\u003cli\u003e€10.9bn aggregate litigation-related outflows (2020-2023)\u003c\/li\u003e\n\u003cli\u003eRequires substantial cash reserves\u003c\/li\u003e\n\u003cli\u003eCosts unpredictable-material to financial strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Infrastructure and IT Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe transition to a data-driven model forces Bayer to keep spending on cloud, cybersecurity, and software-about €1.2-1.5 billion annually in IT through 2025, supporting the digital farming platform and ops efficiency.\u003c\/p\u003e\n\u003cp\u003eLate 2025 IT spend is positioned as a long-term cost reducer: automation targets 10-15% lower SG\u0026amp;A over five years if rollout meets KPI timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€1.2-1.5bn IT spend (2025 est.)\u003c\/li\u003e\n\u003cli\u003eSupports digital farming platform\u003c\/li\u003e\n\u003cli\u003eCybersecurity and cloud prioritized\u003c\/li\u003e\n\u003cli\u003eAutomation could cut SG\u0026amp;A 10-15% by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer cost drivers: R\u0026amp;D, SG\u0026amp;A, litigation, IT and 149 plants amplify COGS risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D, manufacturing, SG\u0026amp;A, legal, and IT drive Bayer's costs: R\u0026amp;D ~11-13% revenue (~€5.5-6.5bn in 2025), SG\u0026amp;A €10.8bn (FY2024), litigation outflows €10.9bn (2020-2023), IT €1.2-1.5bn (2025 est.), and 149 manufacturing sites (2024) raise COGS under input-price volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e11-13% rev; €5.5-6.5bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e€10.8bn (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation\u003c\/td\u003e\n\u003ctd\u003e€10.9bn (2020-2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT\u003c\/td\u003e\n\u003ctd\u003e€1.2-1.5bn (2025 est.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e149 sites (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical product sales are Bayer's main revenue driver, led by prescription drugs in cardiology and oncology; Pharma contributed €15.8 billion of Bayer's €44.1 billion group sales in 2024, buoyed by patent-protected, high-margin drugs like Xarelto and Vitrakvi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrop Protection and Seed Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer earns major revenue from herbicides, fungicides and high-performance seeds-Crop Science reported €18.3 billion in 2024 sales-these products are seasonal and track weather and commodity prices, so FY sales swing with planting seasons and droughts. \u003c\/p\u003e\n\u003cp\u003eBundling seeds with proprietary chemicals raises customer lifetime value; Bayer said integrated packages lift repeat-purchase rates by ~15% in 2023 farmer surveys. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health OTC Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsumer Health OTC sales generate revenue from mass-market brands in nutrition, pain relief and cold remedies; Bayer's Consumer Health division reported 2024 sales of €4.1 billion, offering steadier cash flows than patented Rx drugs and lower exposure to patent cliffs. Aging populations and rising self-care lifted global OTC market growth to ~4.8% CAGR (2020-2024), driving mid-single-digit organic growth in this stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming Subscription Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer is shifting Crop Science toward subscription revenue via digital farming platforms, with recurring fees for analytics and precision insights reducing dependence on seed\/chemical volume; by 2025 digital services contribute an estimated ~5-7% of Crop Science revenue (Crop Science FY2024 sales €22.3bn, implying €1.1-1.6bn potential run-rate).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue: digital subscriptions\u003c\/li\u003e\n\u003cli\u003e2025 share: ~5-7% of Crop Science\u003c\/li\u003e\n\u003cli\u003eFY2024 Crop Science sales: €22.3bn\u003c\/li\u003e\n\u003cli\u003eEstimated digital run-rate: €1.1-1.6bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Intellectual Property Royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer earns recurring, high-margin income by licensing seed-trait technologies and drug formulations to other firms, monetizing R\u0026amp;D where it lacks direct market presence; in 2024 Bayer reported roughly €1.9bn in intellectual property-related revenue across Crop Science and Pharmaceuticals segments, boosting segment margins.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing monetizes R\u0026amp;D without capex\u003c\/li\u003e\n\u003cli\u003eHigh gross margins, low incremental cost\u003c\/li\u003e\n\u003cli\u003e€1.9bn IP-related revenue in 2024 (company reports)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer 2024: €45.1bn revenue mix - Crop Science leads, Pharma \u0026amp; licensing power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharma: €15.8bn (2024) from prescription drugs (Xarelto, Vitrakvi); Crop Science: €22.3bn (2024) from seeds\/chemicals; Consumer Health: €4.1bn (2024) OTC; Digital subscriptions ~5-7% of Crop Science (~€1.1-1.6bn est. 2025); IP\/licensing ~€1.9bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 (€bn)\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\u003c\/td\u003e\n\u003ctd\u003e15.8\u003c\/td\u003e\n\u003ctd\u003ePatented Rx\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrop Science\u003c\/td\u003e\n\u003ctd\u003e22.3\u003c\/td\u003e\n\u003ctd\u003eSeeds\/chemicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Health\u003c\/td\u003e\n\u003ctd\u003e4.1\u003c\/td\u003e\n\u003ctd\u003eOTC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e1.1-1.6\u003c\/td\u003e\n\u003ctd\u003e5-7% est. 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e1.9\u003c\/td\u003e\n\u003ctd\u003eIP revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Model Business Canvas","offers":[{"title":"Default Title","offer_id":53341748756822,"sku":"bayer-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1023\/3954\/3382\/files\/bayer-canvas-business-model.webp?v=1777664657","url":"https:\/\/modelbusinesscanvas.com\/products\/bayer-business-model-canvas","provider":"Model Business Canvas","version":"1.0","type":"link"}